^
    12d
    Successful management of refractory hyperprolactinemia secondary to ectopic prolactin-secreting disseminated peritoneal leiomyomatosis via surgical resection and postoperative leuprorelin therapy: a rare case report. (PubMed, Gynecol Pelvic Med)
    She received bromocriptine (up to 5 mg/day) for 6 months without response. Clinicians should consider extrapituitary prolactin-secreting lesions in patients with treatment-refractory hyperprolactinemia. Genetic evaluation may further elucidate the pathogenesis of such rare entities.
    Journal
    |
    PRLR (Prolactin Receptor 2)
    |
    leuprolide acetate for depot suspension
    13d
    IFOCOS: Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients. (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    tamoxifen • goserelin acetate
    19d
    Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)" (clinicaltrials.gov)
    P=N/A, N=1905, Completed, Takeda | Recruiting --> Completed
    Trial completion
    |
    AR (Androgen receptor)
    |
    leuprolide acetate for depot suspension
    21d
    ADENOFERT: Assisted reproductive technology (ART) and pregnancy outcomes in women with adenomyosis (internal endometriosis) according to stimulation protocol in relation to immunological and endometrial features: a prospective, randomized study (2024-516089-12-00)
    P4, N=500, Recruiting, Azienda Ospedaliero Universitaria Di Modena | Not yet recruiting --> Recruiting
    Enrollment open
    |
    leuprolide acetate for depot suspension
    24d
    A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=88, Recruiting, TerSera Therapeutics LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    goserelin acetate
    26d
    Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2026 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Eligard (leuprolide acetate) • Viadur (leuprorelin implant)
    26d
    Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Feb 2027
    Trial completion date
    |
    Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Viadur (leuprorelin implant)
    27d
    GO39932: A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov)
    P1, N=181, Active, not recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • triptorelin • goserelin acetate • giredestrant (RG6171)
    27d
    GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET (clinicaltrials.gov)
    P3, N=784, Recruiting, The University of Hong Kong | Trial completion date: Mar 2025 --> May 2026
    Trial completion date
    |
    triptorelin
    1m
    PRIMORDIUM: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=692, Active, not recruiting, Janssen Pharmaceutica N.V., Belgium | Trial completion date: Aug 2029 --> Sep 2031
    Trial completion date
    |
    apalutamide • triptorelin • goserelin acetate
    1m
    ASCLEPIuS: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=102, Active, not recruiting, University of Michigan Rogel Cancer Center | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: Nov 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    DRD (DNA Repair Deficiency)
    |
    DDR
    |
    Zejula (niraparib) • abiraterone acetate • leuprolide acetate for depot suspension
    1m
    A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, R-Pharm International, LLC
    New P2 trial
    |
    abiraterone acetate • triptorelin • goserelin acetate